SOUTH SAN FRANCISCO, Calif., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its third quarter 2013 financial results on Tuesday, November 12, 2013 at 4:30 p.m. ET (1:30 p.m. PT). Financial results for the quarter ended September 30, 2013 will be released after market close on November 12, 2013. To access the live conference call, dial 877-847-7188 U.S. or 408-427-3787 International and use the conference ID# 94446159. Individuals may access the live audio webcast at http://investors.hyperiontx.com/events.cfm. A replay of the webcast will be available on the company's website for 30 days following the live event. About Hyperion Therapeutics Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, RAVICTI ® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL ® (sodium phenylbutyrate) Tablets and Powder which it markets in the U.S. The compound is also marketed in ex-U.S. geographies through business partners. For more information, please visit www.hyperiontx.com.
CONTACT: Sylvia Wheeler, Investor Relations (650) 745-7834